ESR1 and breast carcinoma: Moreover, the identification of changes in miRNA expression profiles leads to the determination of miRNA signatures typical to different molecular breast cancer subtypes classified by receptors statuses: ERα+, Her2, and TNBC [59], and can be used as a potential diagnostic or prognostic biomarker [60].